How NYC’s AI and Healthtech Startups Are Carving Out Niche Funding Streams in a Slowing Ma

Two funding rounds announced today highlight how New York City’s startup ecosystem is adjusting to a market that still has ample capital but is growing more discriminating. Hatz AI, which builds an AI platform for managed service providers, raised $24 million in Series A funding to help these firms offer AI tools to small businesses. Meanwhile, Duet, a network supporting nurse practitioners in launching their own primary care clinics, secured $15 million to expand a model that challenges traditional healthcare consolidation. Both deals stand out not just for their size but for their focus on solving specific problems in fragmented industries—an approach that reflects a broader trend in NYC funding, where broad-based scaling strategies are giving way to targeted investments.

Hatz AI’s funding, led by Nadia Partners with additional support from Vestigo Ventures and The Private Shares Fund, brings the company’s cumulative reported equity funding to $26.5 million. Founded in 2023 by Jimmy Hatzell and Aidan Kehoe, the startup operates as a two-sided marketplace: managed service providers use its platform to deliver AI-powered services—such as chatbots, predictive analytics, or workflow automation—to their small business clients, while Hatz AI manages the underlying technology and compliance. The business model addresses a well-known gap: many managed service providers struggle to differentiate themselves in a crowded field, and small businesses often avoid AI tools due to cost and complexity. By positioning itself as a specialized infrastructure layer for AI services, Hatz AI is targeting a segment where demand is rising but the supply chain is still developing. The funding will likely be used to expand its partner network and refine its service offerings, though the company has not yet disclosed specific customer adoption metrics beyond its investor materials.

Duet’s $15 million Series A, backed by Kairos HQ and Lerer Hippeau, follows a similar strategy but in healthcare—a sector where regulatory barriers and industry fragmentation create significant entry challenges. The company, founded by Jonathan Goldberg in 2023, provides nurse practitioners with the operational tools to open and run their own primary care clinics, covering everything from licensing to staffing and revenue management. Goldberg’s background in telehealth suggests Duet is catering to a group increasingly frustrated with corporate healthcare consolidation. The round’s timing is significant: it comes as regulators push to lower healthcare costs by decentralizing care delivery, and as independent practitioners face pressure from private equity-backed consolidators. Duet’s approach—effectively a turnkey solution for nurse-led practices—could appeal in a market where administrative burdens and burnout are driving professionals to seek alternatives. The funding will accelerate its expansion into new markets, though the company has not yet shared details on the number of clinics it currently supports or its patient volume.

Both rounds align with a broader pattern in NYC’s late-2026 funding environment. While October’s record $4.94 billion in capital deployed—dominated by Ramp’s $1.85 billion round—drew the most attention, the city’s smaller but more focused deals reveal where investors are placing bets beyond the usual high-profile winners. Earlier this month, we noted how startups like Daptic, Biotia, and TriGemX Bio were securing funding in deeptech and biotech, sectors where intellectual property and regulatory paths matter more than rapid revenue growth. Hatz AI and Duet extend that trend into adjacent areas: AI infrastructure for small businesses and healthcare operational software. What they share is a focus on solving a distinct problem with a defensible advantage—whether that’s enabling managed service providers to offer AI tools or helping nurse practitioners avoid the overhead of building practices from the ground up.

The contrast with broader market trends is telling. Earlier this year, European founders began turning to NYC for funding, drawn by what analysts described as a shift in investor priorities away from Silicon Valley’s growth-at-all-costs approach. Yet the deals announced today suggest that even in a city with significant capital, the most successful startups are those with a clear vertical focus and a path to profitability—not just those with the fastest growth rates. Hatz AI’s emphasis on managed service providers, for example, reflects a growing recognition that AI adoption among small businesses will likely be driven by intermediaries rather than direct consumer platforms. Similarly, Duet’s model avoids the risks of horizontal healthtech plays by concentrating on a single, underserved professional group.

What remains uncertain is whether these niche strategies can support the valuations that fueled NYC’s recent funding surge. Hatz AI’s $26.5 million in total funding suggests a pre-money valuation likely in the mid-to-high single digits, while Duet’s $22.5 million implies a similar range—far below the nine-figure rounds that defined 2026’s largest deals. The question for investors is whether these companies can quickly demonstrate product-market fit to justify higher valuations, or if they will remain mid-market players in an era where expectations for rapid scaling have adjusted. For founders, the lesson may be straightforward: in a market where capital is plentiful but attention is limited, specialization is becoming the key differentiator.

BioWraptor’s $1.5 million pre-seed round, also announced today, offers a possible indication. The biotech startup, which develops technology to stabilize fragile biomolecules at room temperature, secured backing from early-stage investors and high-net-worth angels, including Pascal and Berangere Marguet of Anima x Alpha Star. While the round is modest, it highlights how deeptech—long a strength of NYC’s biotech scene—is attracting new investment, even as the city’s overall funding activity cools. If Hatz AI and Duet can prove their models are scalable within their respective niches, they may help redefine what success looks like in a period where the focus has shifted away from unlimited growth.

For now, the story of NYC’s funding isn’t just about the total capital raised but about where the money is being directed—and who is benefiting. The answer, increasingly, is the startups that prioritize solving specific problems over chasing broad-scale expansion.

Sources: alleywatch.com